BioTissue Technologies AG
BioTissue AG english
Annual financial statements 2002, Liquidity secured
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
– Annual financial statements 2002
– Liquidity secured
In the past financial year, BioTissue Technologies AG, demonstrated its
leadership in tissue engineering, presenting successful clinical data of its
products. Compared with the prior year, sales rose 84 percent from Euro 1.1
million to Euro 2.1 million. The loss before interest and taxes came to Euro
-6.0 million, 3 percent larger than the prior year’s loss of Euro -5.8 million.
The undiluted loss per share rose from Euro -1.19 to Euro -2.89.
In order to secure the company’s liquidity and despite the difficult financial
market conditions, a private investor furnished the company with capital in the
form of a loan. Despite the difficult financial market conditions, a private
investor has furnished the company with capital in the form of a loan, thus
securing our liquidity levels. In this way, the company’s solvency is assured
for the next two months. At this point in time, together with a group of
investors an overall concept is being structured that covers the financing of
the company going forwards.
In the current business year, the trend for order receipts for the company’s
tissue engineering products is gratifying.
Contact: BioTissue Technologies AG, Dr. Victor Tiegermann, CEO, Engesserstraße
4a/4b, D-79108 Freiburg, Tel. +49 (0) 761 76 76-112, Fax +49 (0) 761 76 76-154,
ir@biotissue-tec.com
end of ad-hoc-announcement (c)DGAP 31.03.2003
——————————————————————————–
WKN: 618061; ISIN: DE0006180615; Index:
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin-Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
310742 Mär 03
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden